Skip to main
SION
SION logo

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 83%
Buy 0%
Hold 0%
Sell 17%
Strong Sell 0%

Bulls say

Sionna Therapeutics Inc. is positioned to potentially capture a significant market opportunity in the cystic fibrosis (CF) treatment landscape, particularly with its innovative approach to directly stabilize the NBD1 protein, which was previously deemed undruggable. The company's proprietary combinations, such as SION-451 and add-on therapies like SION-719, could yield substantial revenue potential, estimating up to $3.2 billion and $900 million worldwide, respectively, if they demonstrate incremental lung function improvements over existing standard of care treatments. The successful development and commercialization of these therapies could transform treatment paradigms, enhance patient outcomes, and ultimately drive strong financial performance for the company.

Bears say

Sionna Therapeutics Inc. faces significant risks that could adversely impact its stock outlook, particularly related to potential safety events and efficacy issues with its drug candidates, which may hinder progress in clinical trials. Additionally, challenges such as lower-than-expected commercial uptake of existing therapies, pricing pressures, and competitive dynamics in the cystic fibrosis market pose further concerns for revenue generation and overall company viability. The presence of potential safety signals and regulatory challenges associated with pipeline programs could result in material setbacks and decrease the probability of successful outcomes, amplifying the company's risk profile.

SION has been analyzed by 6 analysts, with a consensus rating of Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 6 analysts, SION has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.